NCT06319248

MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 308 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to determine if early administration of Midodrine can improve outcomes by maintaining a higher mean blood pressure off of intravenous medications. Researchers want to see if Midodrine can help people with sepsis need fewer vasopressors, which could mean shorter hospital stays, less time with uncomfortable tubes, and a smoother recovery overall.

Conditions

• Sepsis
• Low Blood Pressure

Interventions

Type	Name	Description
DRUG	Midodrine	Subjects will receive standard of care for sepsis and 10 mg of Midodrine every 8 hours administered orally or enterally (via nasogastric tube)
OTHER	Standard of Care	Subjects will receive standard of care for sepsis treatment.

Timeline

• Start date: 2024-05-14
• Primary completion: 2029-05-30
• Completion: 2029-07-30
• First posted: 2024-03-20
• Last updated: 2025-10-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study